Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US9114139B2 · kind B2 · utility
3Cited by
19References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 16, 2014 |
| Grant date | Aug 25, 2015 |
| Priority date | — |
| Expiry date | Jan 16, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y301/04012
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.